PT-141 research: what women gained and what remains unsure
Two final large studies before approval, called Phase 3 trials, found a small average benefit. Shorter work can’t settle every claim.
What the strongest studies found
Did PT-141 help in the main studies? Yes, though the average benefit was small. Two large tests enrolled women who had yet to reach menopause and found their low desire very troubling. Compared with an empty placebo shot, the medicine brought a slight added gain [3]; both tests found about the same modest difference. Reviewers still disagree over how much you would notice in daily life [3]. Small male studies hinted at help with erections, but approval never followed. Firm proof therefore applies to one narrow group, not to everyone seeking help.
What the drug changes inside the brain
PT-141 turns on controls inside the brain [1]. This early work was limited and relied mostly on animals. Rats and monkeys both developed erections after the drug. Cells linked with sex and hunger in the brain also became active [1]. Animal work can guide the next test, but it doesn’t forecast your own response.
Small tests of PT-141 in men found that higher amounts brought erections sooner and made them firmer [1]. That hint didn’t prove a treatment you can count on. Blood vessels weren’t the main target in these results. PT-141 may affect wanting first, while common erection pills mainly make filling the penis easier.
What changed in rats and then in women
The first work used female rats, not women. PT-141 made the rats show more interest in sex without raising their general movement [2], while other mating acts changed little. That result suggests desire rather than simple motion, but it doesn’t predict a woman’s response.
A small human study followed in 2022. It enrolled 31 women who had yet to go through menopause and whose low desire caused deep trouble. Each woman received the medicine at one visit and a placebo at another. The women and the study staff didn’t know which shot had been given until the test ended. The desire gain remained for up to 24 hours [5]. While sexual scenes played, scans showed a stronger response in brain parts linked with sexual interest. The small group limits how much you can take from that result.
What the two large Phase 3 trials before approval showed
The two main Phase 3 studies were the big trials that came before approval. Called 301 and 302, they followed 1,267 women who had yet to reach menopause and found low desire seriously troubling [3]. Each woman used an under-the-skin shot of 1.75 mg as needed, and both studies ran for 24 weeks.
Set question sheets asked how much desire the women felt and how badly low desire troubled them. One question, called item 13, asked about that strain. The drug had a slight edge on both measures. The source records the checks as P<.001 and P<.001 [3]; in plain words, mere chance was unlikely to explain either result, but the figures don’t show how much you would notice.
A 52-week follow-up watched 684 women who knew they were getting the drug. The modest desire gain remained, and all harms were already known [4]. Nausea affected 40.4%, flushing 20.6%, and headache 12.0% [4]. A later review considered whether you might find that tradeoff worthwhile in daily life [3].
What PT-141 changed before the prescription note
The PT-141 benefits supported by the trials are specific and bounded: in premenopausal women with HSDD, an as-needed 1.75 mg subcutaneous dose produced a statistically significant rise in sexual desire and a statistically significant drop in the distress that low desire caused, sustained across a year of open-label use [3][4]. Both coprimary endpoints were met in both pivotal trials — a reproducible result, not a one-trial fluke [3].
Honesty about magnitude is part of the record. The effect sizes — an integrated FSFI-desire gain of +0.35 and an FSDS-DAO item-13 reduction of -0.33 — are statistically real but clinically modest, and that is exactly how the regulatory and review literature frames them [3]. Critical re-analyses have argued these effects on desire and distress are small and have questioned the clinical meaningfulness of the chosen outcome measures [3]. An integrated safety analysis across the development program confirmed the tolerability profile, with nausea, flushing, and headache as the leading treatment-emergent events [3]. The benefit is genuine; it is not large.
PT-141 is a prescription-only medication; Promise Peptides (mypromise.com) sits in the clinician-led telehealth category, where licensed prescribers review individual requests and may decline them.
What small male and animal studies can’t prove
Evidence outside the approved use is far weaker. Small male tests tried a nose spray at several amounts. Erections improved as the amount rose, but approval never came [1]. The spray reached the blood unevenly, so its makers dropped it. A 2008 study by Safarinejad and Hosseini now carries serious doubt. In 2023, the journal posted an Expression of Concern, warning that the work could be unsound [3]. You can’t treat that study as firm proof.
In 2025, scientists worked with female Syrian hamsters rather than women. They examined brain cells tied to drive and learned reward. Low and high amounts of bremelanotide didn’t change the messages they measured. The drug also didn’t increase the reward those hamsters had learned from sex [3]. A 2025 review listed bremelanotide as one choice among several, not the best one [3]. PT-141 dosage explains the tested amounts. The male evidence explains why it remains weak.